Epidemic response to COVID-19 in pharmaceutical and healthcare industries series - Issue 2

The outbreak of Coronavirus Disease 2019 (COVID-19) has caused enormous challenges to China’s economy and people’s lives. With the epidemic on the rise, society has paid more attention to the healthcare and pharmaceutical industries, which will impose both positive and negative consequences across different sub-sectors. In the short term, there will be a variety of impacts on pharma companies, healthcare institutions, pharmaceutical distribution and retail, and health insurance.

In the medium to long-term, the impact on the healthcare and pharmaceutical industries are relatively positive.

Contact us

Mark Gilbraith

China Consulting, Consumer, Health and Technology Industry Leader, PwC China

Tel: +[86] (21) 2323 2898

Jia Xu

Pharma and Healthcare Consulting Leader, PwC China

Tel: +[86] (10) 6533 7734

Jingyu Cai

Partner, PwC China

Tel: +[86] (21) 2323 3005

Follow us